Trump administration proposes policy to increase European pharmaceutical pricing

The Trump administration is seeking to force European nations to pay higher prices for brand-name pharmaceuticals, mirroring previous demands for increased defense spending. The policy faces significant pushback from European stakeholders and creates operational uncertainty for multinational pharmaceutical firms, though the specific implementation mechanisms remain unclear.